Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc. is strategically advancing its position in the oncology sector, highlighted by the recent operational expansions of its CNSide Diagnostics, which include securing new laboratory licenses in California, Rhode Island, and Maryland. The company has also received a significant $18 million grant from the Cancer Prevention and Research Institute of Texas, bolstering its research initiatives and reinforcing its commitment to develop therapies for leptomeningeal metastases. Furthermore, ongoing improvements in operational capacity and the potential for enhanced national payor coverage could lead to increased test volumes and early revenue generation from the CNSide CSF assay as Plus Therapeutics progresses through key milestones in drug development.

Bears say

Plus Therapeutics Inc faces significant risks that could negatively impact its stock performance, primarily stemming from the potential failure of its product candidates, including rhenium (186Re) obisbemeda, to show safety and efficacy in clinical trials. Additionally, the company may encounter obstacles in obtaining regulatory approval for its therapies, as well as challenges related to securing suitable reimbursement and facing competition within the pharmaceutical market. The influence of changing macroeconomic factors further compounds these risks, creating an uncertain financial outlook for the company.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.